<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38066618</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Reducing sick leave, improving work ability, and quality of life in patients with mild to moderate Long COVID through psychosocial, physiotherapeutic, and nutritive supportive digital intervention (MiLoCoDaS): study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>798</StartPage><MedlinePgn>798</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">798</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-023-07819-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Following &#xfeff;SARS-CoV-2 infection, a relevant proportion of patients suffer from persistent or recurring sequela, even after initially mild primary illness. Many patients experience exhaustion and fatigue, rendering them incapable of working. Long COVID exerts a substantial burden on society and the healthcare system: at least 65 million people are currently affected worldwide. The underlying pathobiology is a complex derangement in several organ systems. To date, causal pharmaceutical therapies remain elusive. Waiting lists for specialist care are long. Rapidly scalable digital interventions offering support for the frequent subgroup of patients with mild to moderate impairment from Long COVID are urgently needed. The MiLoCoDaS study compares three intensities of a potentially rapidly scalable digital intervention aiming to accelerate recovery. The overall objective is to figure out if there is a difference in the effect sizes between these modalities.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The online intervention uses a learning platform (LMS, TYPO3 framework) comprising 12 sessions of medical, psychological, physiotherapeutic, and nutritional content. The three modalities differ as follows: patient information only (sham intervention, control), information plus interactive digital workbook including practical exercises (digital intervention), and the digital workbook augmented by once-weekly online seminars and discussion groups (person and peer-contact). Eligible patients are 18-67 years old satisfying Long COVID diagnostic criteria. Patients are recruited through primary care physicians and randomly allocated. The primary endpoint is the number of sick leave days during the 6-month observation period; secondary endpoints are patient-reported symptoms, quality of life, and work ability. The study size provides a power of 80% at a type I error of &lt; 0.05 to show an effect size of Cohen = 0.3 between the augmented and the sham intervention (N = 152 per arm, total accounting for attrition N = 600).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">If one of the two interventions is superior to providing information alone, MiLoCoDaS would provide the starting point for a rapidly scalable digital intervention for the frequent and currently underserved patient group with mild to moderate impairment from Long COVID. Several caveats pertain to the heterogeneity of Long COVID manifestation and duration prior to inclusion. It is conceivable that the possible effect of the intervention may differ across subgroups. Therefore, a priori defined secondary analysis will be conducted.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">German Clinical Trials Register (DRKS) DRKS00028964. Registered on 24 August 2022.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krotz</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0009-0494-4440</Identifier><AffiliationInfo><Affiliation>Center for Preventive Medicine and Digital Health (CPD), Division of General Medicine, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany. adrian.krotz@medma.uni-heidelberg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sosnowsky-Waschek</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Applied Psychology, SRH University of Applied Sciences Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechtel</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Preventive Medicine and Digital Health (CPD), Division of General Medicine, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Preventive Medicine and Digital Health (CPD), Division of General Medicine, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohkamp</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Therapeutic Sciences, SRH University of Applied Sciences Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Applied Digital Product Development, SRH Berlin University of Applied Sciences, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genser</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>High5Data, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Joachim E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Center for Preventive Medicine and Digital Health (CPD), Division of General Medicine, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018582" MajorTopicYN="N">Sick Leave</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014938" MajorTopicYN="N">Work Capacity Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Digital intervention</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Long-term follow-up</Keyword><Keyword MajorTopicYN="N">Post-COVID condition</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Psychological support</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">Sick leave</Keyword><Keyword MajorTopicYN="N">Work ability</Keyword></KeywordList><CoiStatement>The Primary Sponsor is a shareholder in the LMS service provider and the Principal Investigator is a part-time employee of the LMS service provider. Since the LMS service provider only provides the technology, maintains it, and provides technical support, but has no ownership claims to any content placed there, a subordinate conflict of interest is to be postulated, if one is assumed at all. The contract was awarded by regular public tender. NSW owns the company that provides the webinar coaches for the high-intensity intervention arm.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>0</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38066618</ArticleId><ArticleId IdType="pmc">PMC10709981</ArticleId><ArticleId IdType="doi">10.1186/s13063-023-07819-7</ArticleId><ArticleId IdType="pii">10.1186/s13063-023-07819-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Centre for Disease Prevention and Control (ECDC): Prevalence of post COVID-19 condition symptoms: a systematic review and meta-analysis of cohort study data, stratified by recruitment setting. https://www.ecdc.europa.eu/en/publications-data/prevalence-post-covid-19-condition-symptoms-systematic-review-and-meta-analysis (2022). Accessed 17 Mar 2023.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3&#xa0;months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4) 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023:55. 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>d'Ettorre G, Gentilini Cacciola E, Santinelli L, De Girolamo G, Spagnolello O, Russo A, Tarsitani L, Ciccozzi M, Mastroianni CM, d'Ettorre G, et al. Covid-19 sequelae in working age patients: a systematic review. J Med Virol. 2022;94(3):858&#x2013;868. doi: 10.1002/jmv.27399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27399</ArticleId><ArticleId IdType="pmc">PMC8661973</ArticleId><ArticleId IdType="pubmed">34655247</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2013;167. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A, Kudryavtsev I, Starshinova A, Kudlay D, Zinchenko Y, Glushkova A, Yablonskiy P, Shoenfeld Y. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021;10(11):1408. doi: 10.3390/pathogens10111408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10111408</ArticleId><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, Navarro-Santana M. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55&#x2013;70. doi: 10.1016/j.ejim.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Nieters A, Kr&#xe4;usslich H-G, Brockmann SO, G&#xf6;pel S, Kindle G, Merle U, Steinacker JM, Rothenbacher D, Kern WV. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379:e071050. doi: 10.1136/bmj-2022-071050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071050</ArticleId><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Techniker Krankenkasse. Gesundheitsreport 2022 &#x2013; Zwei Jahre Coronapandemie: Wie geht es Deutschlands Besch&#xe4;ftigten? Teil 2. 2022. https://www.tk.de/resource/blob/2130932/70a0d93d19f6444f06310379441bd046/gesundheitsreport-2022-data.pdf. Accessed 17 Mar 2023</Citation></Reference><Reference><Citation>German Federal Institute for Occupational Safety and Health (BAuA). Volkswirtschaftliche Kosten durch Arbeitsunf&#xe4;higkeit 2021 (Economic Costs due to Incapacity for Work 2021). 2022. https://www.baua.de/DE/Themen/Arbeitswelt-und-Arbeitsschutz-im-Wandel/Arbeitsweltberichterstattung/Kosten-der-AU/pdf/Kosten-2021.pdf?__blob=publicationFile&amp;v=3. Accessed 17 Mar 2023</Citation></Reference><Reference><Citation>Daniel K. Who gets Long COVID and suffers its mental health and socioeconomic consequences in the United States? Preliminary findings from a large nationwide study. medRxiv. 2023: 2023.01.06.23284199. 10.1101/2023.01.06.23284199.</Citation></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, et al. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459. doi: 10.3389/fimmu.2023.1129459.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1129459</ArticleId><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeinafshar A, Yazdanpanah N, Rezaei N. Immune-based therapeutic approaches in COVID-19. Biomed Pharmacother. 2022;151:113107. doi: 10.1016/j.biopha.2022.113107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113107</ArticleId><ArticleId IdType="pmc">PMC9108029</ArticleId><ArticleId IdType="pubmed">35594701</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti V, Corbi G, Sabbatino F, De Pascale D, Sellitto C, Stefanelli B, et al. Long COVID: clinical framing, biomarkers, and therapeutic approaches. J Pers Med. 2023;13(2) 10.3390/jpm13020334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9959656</ArticleId><ArticleId IdType="pubmed">36836568</ArticleId></ArticleIdList></Reference><Reference><Citation>Strecher VJ, Kreuter M, Den Boer DJ, Kobrin S, Hospers HJ, Skinner CS. The effects of computer-tailored smoking cessation messages in family practice settings. J Fam Pract. 1994;39(3):262&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">8077905</ArticleId></ArticleIdList></Reference><Reference><Citation>Andayani RHR, Luhpuri D, Hakim MZ, Fahrudin A. Digital therapy in rehabilitation service for mental health patients during COVID-19 pandemic: Opportunity and challenges. Int J Health Sci. 2022;6(2):1001&#x2013;1012. doi: 10.53730/ijhs.v6n2.9698.</Citation><ArticleIdList><ArticleId IdType="doi">10.53730/ijhs.v6n2.9698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz J, Offidani E, Taraboanta L, Lakhan SE, Campellone TR. Appropriate controls for digital therapeutic clinical trials: a narrative review of control conditions in clinical trials of digital therapeutics (DTx) deploying psychosocial, cognitive, or behavioral content. Front Digit Health. 2022;4:823977. doi: 10.3389/fdgth.2022.823977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fdgth.2022.823977</ArticleId><ArticleId IdType="pmc">PMC9436387</ArticleId><ArticleId IdType="pubmed">36060538</ArticleId></ArticleIdList></Reference><Reference><Citation>Werntz A, Amado S, Jasman M, Ervin A, Rhodes JE. Providing human support for the use of digital mental health interventions: systematic meta-review. J Med Internet Res. 2023;25:e42864. doi: 10.2196/42864.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/42864</ArticleId><ArticleId IdType="pmc">PMC9941905</ArticleId><ArticleId IdType="pubmed">36745497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Z, Li W, Zhu R. Online psychosocial interventions for improving mental health in people during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2022;316:120&#x2013;131. doi: 10.1016/j.jad.2022.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2022.08.023</ArticleId><ArticleId IdType="pmc">PMC9373538</ArticleId><ArticleId IdType="pubmed">35970325</ArticleId></ArticleIdList></Reference><Reference><Citation>Witteveen AB, Young S, Cuijpers P, Ayuso-Mateos JL, Barbui C, Bertolini F, Cabello M, Cadorin C, Downes N, Franzoi D, et al. Remote mental health care interventions during the COVID-19 pandemic: an umbrella review. Behav Res Ther. 2022;159:104226. doi: 10.1016/j.brat.2022.104226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brat.2022.104226</ArticleId><ArticleId IdType="pmc">PMC9661449</ArticleId><ArticleId IdType="pubmed">36410111</ArticleId></ArticleIdList></Reference><Reference><Citation>von Zweck C, Naidoo D, Govender P, Ledgerd R. Current practice in occupational therapy for COVID-19 and post-COVID-19 conditions. Occup Ther Int. 2023;2023:5886581. doi: 10.1155/2023/5886581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/5886581</ArticleId><ArticleId IdType="pmc">PMC10219768</ArticleId><ArticleId IdType="pubmed">37250066</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshe I, Terhorst Y, Philippi P, Domhardt M, Cuijpers P, Cristea I, Pulkki-Raback L, Baumeister H, Sander LB. Digital interventions for the treatment of depression: a meta-analytic review. Psychol Bull. 2021;147(8):749&#x2013;786. doi: 10.1037/bul0000334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/bul0000334</ArticleId><ArticleId IdType="pubmed">34898233</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido S, Millington C, Cheers D, Boydell K, Schubert E, Meade T, Nguyen QV. What works and what doesn&#x2019;t work? A systematic review of digital mental health interventions for depression and anxiety in young people. Front Psychiatry. 2019;10:759. doi: 10.3389/fpsyt.2019.00759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00759</ArticleId><ArticleId IdType="pmc">PMC6865844</ArticleId><ArticleId IdType="pubmed">31798468</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson SB, von Feilitzen GS, Andersson ME, Sikora P, Lindh M, Nord&#xe9;n R, Nilsson S, Sigstr&#xf6;m R. Self-reported symptom severity, general health, and impairment in post-acute phases of COVID-19: retrospective cohort study of Swedish public employees. Sci Rep. 2022;12(1):19818. doi: 10.1038/s41598-022-24307-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-24307-1</ArticleId><ArticleId IdType="pmc">PMC9672032</ArticleId><ArticleId IdType="pubmed">36396860</ArticleId></ArticleIdList></Reference><Reference><Citation>Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.1. Health Qual Life Outcomes. 2007;5(1):54. doi: 10.1186/1477-7525-5-54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-5-54</ArticleId><ArticleId IdType="pmc">PMC2065865</ArticleId><ArticleId IdType="pubmed">17825096</ArticleId></ArticleIdList></Reference><Reference><Citation>Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry. 2015;37(1):67&#x2013;75. doi: 10.1016/j.genhosppsych.2014.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2014.09.009</ArticleId><ArticleId IdType="pubmed">25439733</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron IM, Crawford JR, Lawton K, Reid IC. Psychometric comparison of PHQ-9 and HADS for measuring depression severity in primary care. Br J Gen Pract. 2008;58(546):32&#x2013;36. doi: 10.3399/bjgp08X263794.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp08X263794</ArticleId><ArticleId IdType="pmc">PMC2148236</ArticleId><ArticleId IdType="pubmed">18186994</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092&#x2013;1097. doi: 10.1001/archinte.166.10.1092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz MA, Zamorano E, Garc&#xed;a-Campayo J, Pardo A, Freire O, Rejas J. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord. 2011;128(3):277&#x2013;286. doi: 10.1016/j.jad.2010.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.07.010</ArticleId><ArticleId IdType="pubmed">20692043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen T, Borritz M, Villadsen E, Christensen K. The Copenhagen Burnout Inventory: a new tool for the assessment of burnout. Work Stress. 2005;19:192&#x2013;207. doi: 10.1080/02678370500297720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02678370500297720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuzfeld S, Seibt R, Kumar M, Rieger A, Stoll R. German version of the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ): translation and validation. J Occup Med Toxicol. 2016;11(1):13. doi: 10.1186/s12995-016-0100-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12995-016-0100-2</ArticleId><ArticleId IdType="pmc">PMC4807584</ArticleId><ArticleId IdType="pubmed">27019667</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaglio J, Conard M, Poston WS, O'Keefe J, Haddock CK, House J, Spertus JA. Testing the performance of the ENRICHD Social Support Instrument in cardiac patients. Health Qual Life Outcomes. 2004;2(1):24. doi: 10.1186/1477-7525-2-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-2-24</ArticleId><ArticleId IdType="pmc">PMC434528</ArticleId><ArticleId IdType="pubmed">15142277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendel F, Spaderna H, Sieverding M, Dunkel A, Lehmkuhl E, Hetzer R, Regitz-Zagrosek V. Eine deutsche Adaptation des ENRICHD Social Support Inventory (ESSI) Diagnostica. 2011;57(2):99&#x2013;106. doi: 10.1026/0012-1924/a000030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1026/0012-1924/a000030</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;s K, Abel T, Woll A, Niemann S, Tittlbach S, Schott N. Der Fragebogen zur Erfassung des motorischen Funktionsstatus (FFB-Mot) Diagnostica. 2002;48(2):101&#x2013;111. doi: 10.1026//0012-1924.48.2.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1026//0012-1924.48.2.101</ArticleId></ArticleIdList></Reference><Reference><Citation>German Federal Institute for Occupational Safety and Health (BAuA): Work Ability Index (WAI). https://www.baua.de/EN/Topics/Work-and-health/Mental-health/Mental-health-and-cognitive-capacity/Work-Ability-Index.html (2023). Accessed 17 Mar 2023.</Citation></Reference><Reference><Citation>Ilmarinen J. The Work Ability Index (WAI) Occup Med. 2007;57(2):160. doi: 10.1093/occmed/kqm008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqm008</ArticleId></ArticleIdList></Reference><Reference><Citation>Topp CW, &#xd8;stergaard SD, S&#xf8;ndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167&#x2013;176. doi: 10.1159/000376585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000376585</ArticleId><ArticleId IdType="pubmed">25831962</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;we B, Spitzer RL, Gr&#xe4;fe K, Kroenke K, Quenter A, Zipfel S, Buchholz C, Witte S, Herzog W. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians&#x2019; diagnoses. J Affect Disord. 2004;78(2):131&#x2013;140. doi: 10.1016/S0165-0327(02)00237-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0327(02)00237-9</ArticleId><ArticleId IdType="pubmed">14706723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall T, Krahn GL, Horner-Johnson W, Lamb G. Examining functional content in widely used Health-Related Quality of Life scales. Rehabil Psychol. 2011;56(2):94&#x2013;99. doi: 10.1037/a0023054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0023054</ArticleId><ArticleId IdType="pubmed">21574727</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger T, Zimmermann J, Huffziger S, Ubl B, Diener C, Kuehner C, Grosse HM. Measuring depression with a well-being index: further evidence for the validity of the WHO Well-Being Index (WHO-5) as a measure of the severity of depression. J Affect Disord. 2014;156:240&#x2013;244. doi: 10.1016/j.jad.2013.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2013.12.015</ArticleId><ArticleId IdType="pubmed">24412323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmings P, Prinz C. Sickness and disability systems: comparing outcomes and policies in Norway with those in Sweden, the Netherlands and Switzerland. 2020. 10.1787/c768699b-en.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>